タナカ　ジユンジ   TANAKA Junji   田中　淳司    所属   その他 その他    職種   非常勤嘱託
論文種別	総説
言語種別	英語
査読の有無	査読あり
表題	Recent progress in and challenges in cellular therapy using NK cells for hematological malignancies.
掲載誌名	正式名：Blood reviews 略　 称：Blood Rev ISSNコード：15321681/0268960X
掲載区分	国外
巻・号・頁	44,pp.100678
著者・共著者	Tanaka Junji†*, Miller Jeffrey S
担当区分	筆頭著者,責任著者
発行年月	2020/11
概要	NK cells have killing activity against leukemic cells and solid cancer cells that escape from T cell recognition because of the low expression level of HLA class I molecules. This characteristic feature of NK cell recognition of target cells in contrast to T cells provides a strategy to overcome tolerance in cancer and leukemia patients. A strong alloreactive NK cell-mediated anti-leukemia effect can be induced in haploidentical hematopoietic stem cell transplantation. Also, NK cells can be expanded by several methods for adoptive immunotherapy for hematological malignancies and other malignant diseases. We review the historical role of NK cells and recent approaches to enhance the functions of NK cells, including ex vivo expansion of autologous and allogenic NK cells, checkpoint receptor blockade, and the use of memory-like NK cells and CAR-NK cells, for treatment of hematological malignancies.
DOI	10.1016/j.blre.2020.100678
PMID	32229065